SVA
Sinovac Biotech Ltd
6.50$
+0.0%
vs. previous close
Closing price · As of: Sep 12, 2026
Statements
Income Statement
Sinovac Biotech Ltd (SVA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q4 23), "Revenue" came in at 308 million $. Tick rows to compare them in a chart.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 13 | Q2 13 | Q3 13 | Q4 13 | Q1 14 | Q2 14 | Q3 14 | Q4 14 | Q1 15 | Q2 15 | Q3 15 | Q4 15 | Q1 16 | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q2 22 | Q3 22 | Q1 23 | Q2 23 | Q4 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 17 | 22 | 14 | 14 | 12 | 17 | 20 | 9.2 | 18 | 17 | 11 | 11 | 1.4 | 29 | 31 | 33 | 67 | 31 | 107 | 47 | 75 | 54 | 37 | 37 | 64 | 64 | 15 | 15 | 52 | 115 | 327 | 327 | 10,981 | 8,394 | 1,212 | 280 | 1,682 | 140 | 308 | |
| 3.0 | 3.9 | 7.5 | 3.3 | 3.3 | 3.0 | 5.0 | 5.2 | 2.3 | 3.3 | 5.5 | 4.6 | 4.6 | 3.7 | 5.7 | 8.3 | 3.9 | 7.7 | 8.3 | 13 | 2.8 | 11 | 4.7 | 3.8 | 3.8 | 6.1 | 10 | 2.0 | 2.0 | 7.6 | 14 | 44 | 44 | 632 | 440 | 254 | 430 | 1,304 | 188 | – | |
| 7.1 | 14 | 15 | 10 | 10 | 9.1 | 12 | 15 | 6.9 | 15 | 11 | 6.3 | 6.3 | -2.4 | 23 | 23 | 30 | 59 | 23 | 95 | 45 | 65 | 49 | 33 | 33 | 58 | 54 | 13 | 13 | 45 | 101 | 284 | 284 | 10,349 | 7,953 | 958 | -150 | 378 | -48 | 308 | |
| 1.8 | 2.0 | 2.0 | 1.7 | 1.7 | 3.3 | 2.5 | 3.5 | 2.2 | 2.2 | 2.2 | 2.1 | 2.1 | 2.8 | 4.2 | 3.6 | 4.4 | 8.8 | 3.6 | 12 | 4.2 | 5.9 | 4.7 | 4.5 | 4.5 | 6.3 | 5.7 | 5.7 | 5.7 | 14 | 26 | 2.7 | 2.7 | 54 | 101 | 184 | 258 | 399 | 151 | 193 | |
| 6.7 | 8.9 | 11 | 6.3 | 9.7 | 12 | 11 | 9.3 | 6.7 | 9.2 | 10 | 11 | 6.5 | 8.6 | 13 | 16 | 18 | 46 | 1,708 | 63 | 25 | 45 | 28 | 67 | 23 | 31 | 34 | 33 | 17 | 31 | 47 | 83 | – | – | – | – | – | – | – | – | |
| 9.3 | 11 | 12 | 9.7 | 9.7 | 12 | 11 | 13 | 8.9 | 11 | 13 | 8.0 | 8.0 | 11 | 17 | 13 | 27 | 46 | 13 | 63 | 30 | 51 | 33 | 28 | 28 | 37 | 40 | 22 | 22 | 45 | 74 | 87 | 87 | 216 | 533 | 341 | 929 | 1,069 | 383 | 370 | |
| -2.2 | 2.2 | 3.0 | 1.5 | 0.6 | -3.0 | 0.9 | 1.9 | -2.0 | 4.3 | -1.3 | -1.2 | -1.8 | -14 | 6.1 | 10.0 | 6.6 | 13 | 10.0 | 32 | 15 | 14 | 16 | 5.0 | 5.0 | 21 | 14 | -8.8 | -8.8 | -0.2 | 28 | 197 | 197 | 10,133 | 7,420 | 617 | -1,078 | -202 | -431 | -123 | |
| 0.7 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | 0.9 | 0.6 | 0.4 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.6 | 0.4 | 0.8 | 0.6 | 0.7 | 0.4 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.4 | 0.5 | 0.3 | 0.3 | 1.5 | 1.3 | 0.6 | 0.6 | 2.5 | 0.3 | 2.0 | |
| -2.4 | 1.9 | 2.9 | 0.8 | 0.8 | -2.9 | 0.5 | 2.8 | -2.1 | 4.1 | -1.5 | -1.6 | -1.6 | -14 | 5.8 | 9.4 | 6.4 | 13 | 9.4 | 32 | 15 | 14 | 17 | 5.2 | 5.2 | 22 | 15 | -8.5 | -8.5 | -0.1 | 27 | 198 | 198 | 6,678 | 4,893 | 620 | -570 | -200 | -17 | -89 | |
| 0.0 | 0.0 | 0.1 | 0.3 | 0.3 | 0.1 | 0.4 | 0.6 | 0.6 | 0.4 | 0.3 | -0.1 | -0.1 | -1.4 | 1.5 | 2.6 | -1.5 | -3.0 | 2.6 | 11 | 2.9 | 3.7 | 3.5 | 1.6 | 1.6 | 4.5 | 2.9 | -1.1 | -1.1 | 1.2 | 5.7 | 26 | 26 | 1,570 | 1,534 | 136 | -199 | -115 | -34 | 139 | |
| -2.0 | 1.3 | 2.3 | 0.4 | 0.0 | -2.2 | 0.1 | 1.3 | -2.3 | 2.3 | -1.6 | -1.6 | 1.3 | -9.6 | 3.2 | 4.4 | 5.4 | 11 | 4.4 | 15 | 8.4 | 5.7 | 8.9 | 3.6 | 1.8 | 12 | 7.8 | -7.4 | -5.9 | -3.8 | 11 | 173 | 109 | 5,108 | 3,359 | 485 | -371 | -85 | 17 | -117 | |
| 0.0 | 4.5 | 5.3 | 4.2 | 4.2 | -0.1 | 2.2 | 5.8 | 0.1 | 6.3 | 0.5 | 0.3 | 0.2 | -12 | 7.4 | 8.7 | – | 15 | 11 | 35 | 17 | 16 | 18 | 6.5 | 6.4 | 23 | 16 | -7.4 | -7.4 | 1.9 | 28 | 200 | 200 | 10,150 | 7,471 | 695 | -822 | -207 | 21 | -27 |
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: September 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.